Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2007

Open Access 01-02-2007 | Research article

Risk of second primary cancer in men with breast cancer

Authors: Sacha Satram-Hoang, Argyrios Ziogas, Hoda Anton-Culver

Published in: Breast Cancer Research | Issue 1/2007

Login to get access

Abstract

Introduction

A retrospective registry-based cohort study was conducted to examine the risk of second primary cancer following the occurrence of breast cancer in males.

Methods

Data obtained from the California Cancer Registry in the period 1988 to 2003 included 1,926 men aged 85 years and younger diagnosed with a first primary breast cancer. Person-year analysis was applied to determine the risk of second primary cancers after the occurrence of a first primary breast cancer. The effects of age, race, and time since the first breast cancer diagnosis were assessed.

Results

Of the 1,926 male breast cancer cases, 221 (11.5%) developed a second primary cancer. Men with first incidence of breast cancer have a significantly higher risk of second cancer (standardized incidence ratio (SIR) = 1.16, 95% confidence interval (CI) = 1.01–1.32). The risk of a second site-specific cancer is elevated for breast cancer (SIR = 52.12, 95% CI = 31.83–80.49), cutaneous melanoma (SIR = 2.98, 95% CI = 1.63–5.00) and stomach cancer (SIR = 2.11, 95% CI = 1.01–3.88). There is a general tendency towards higher risks of second malignancies among younger men compared to older men and the risk increased with the passage of time.

Conclusion

Male breast cancer patients should be monitored carefully for the occurrence of second primary cancers, especially a second primary breast cancer.
Literature
1.
Horn-Ross PL: Multiple primary cancers involving the breast. Epidemiol Rev. 1993, 1: 169-176.CrossRef
2.
Shapiro CL, Recht A: Late effects of adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr. 1994, (16): 101-112.
3.
Frank TS: Hereditary cancer syndromes. Arch Pathol Lab Med. 2001, 125: 85-90.PubMed
4.
Dong C, Hemminki K: Second primary breast cancer in men. Breast Cancer Res Treat. 2001, 66: 171-172. 10.1023/A:1010639429207.CrossRefPubMed
5.
Auvinen A, Curtis RE, Ron E: Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst. 2002, 94: 1330-1332.CrossRefPubMed
6.
Hemminki K, Scelo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride M, Kliewer EV, et al: Second primary malignancies in patients with male breast cancer. Br J Cancer. 2005, 92: 1288-1292. 10.1038/sj.bjc.6602505.CrossRefPubMedPubMedCentral
7.
Kwong SL, Wright WE: Cancer in California. 2003, Sacramento, CA: California Department of Health Services, Cancer Surveillance Section
8.
Liede A, Karlan BY, Narod SA: Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004, 22: 735-742. 10.1200/JCO.2004.05.055.CrossRefPubMed
9.
Marsh D, Zori R: Genetic insights into familial cancers-update and recent discoveries. Cancer Lett. 2002, 181: 125-164.CrossRefPubMed
10.
The Breast Cancer Linkage Consortium: Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999, 91: 1310-1316. 10.1093/jnci/91.15.1310.CrossRef
11.
Thompson D, Easton DF, Breast Cancer Linkage Consortium: Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002, 94: 1358-1365.CrossRefPubMed
12.
Kirkpatrick CS, Lee JA, White E: Melanoma risk by age and socio-economic status. Int J Cancer. 1990, 46: 1-4.CrossRefPubMed
13.
Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C: High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000, 92: 1260-1266. 10.1093/jnci/92.15.1260.CrossRefPubMed
14.
Debniak T, Gorski B, Huzarski T, Byrski T, Cybulski C, Mackiewicz A, Gozdecka-Grodecka S, Gronwald J, Kowalska E, Haus O, et al: A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet. 2005, 42: 763-765. 10.1136/jmg.2005.031476.CrossRefPubMedPubMedCentral
15.
Vaughan TL, Davis S, Kristal A, Thomas DB: Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1995, 4: 85-92.PubMed
16.
Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, et al: Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1998, 90: 150-155. 10.1093/jnci/90.2.150.CrossRefPubMed
17.
Thomas DB, Jimenez LM, McTiernan A, Rosenblatt K, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF: Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol. 1992, 135: 734-748.CrossRefPubMed
18.
Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A: Risk factors for male breast cancer – a case-control study from Scandinavia. Acta Oncol. 2001, 40: 467-471.CrossRefPubMed
19.
Hsing AW, McLaughlin JK, Cocco P, Co Chien HT, Fraumeni JF: Risk factors for male breast cancer (United States). Cancer Causes Control. 1998, 9: 269-275. 10.1023/A:1008869003012.CrossRefPubMed
20.
Johnson KC, Pan S, Mao Y, Canadian Cancer Registries Epidemiology Research Group: Risk factors for male breast cancer in Canada, 1994–1998. Eur J Cancer Prev. 2002, 11: 253-263. 10.1097/00008469-200206000-00009.CrossRefPubMed
21.
Casagrande JT, Hanisch R, Pike MC, Ross RK, Brown JB, Henderson BE: A case-control study of male breast cancer. Cancer Res. 1988, 48: 1326-1330.PubMed
22.
Kwong SL, Perkins CI, Morris CR, Cohen R, Allen M, Wright WE: Cancer in California 1988–1999. 2001, Sacramento, CA: California Department of Health Services, Cancer Surveillance Section
Metadata
Title
Risk of second primary cancer in men with breast cancer
Authors
Sacha Satram-Hoang
Argyrios Ziogas
Hoda Anton-Culver
Publication date
01-02-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1643

Other articles of this Issue 1/2007

Breast Cancer Research 1/2007 Go to the issue

Research article

Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study

Editorial

The continuing search for cancer-causing somatic mutations

Research article

An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ

Research article

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

Research article

Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity

Review

Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis!
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits